O	0	9	Promoting
O	10	14	bone
O	15	21	health
O	22	32	management
O	33	35	in
O	36	41	women
O	42	51	diagnosed
O	52	56	with
O	57	63	breast
O	64	70	cancer
O	70	71	:
O	72	73	a
O	74	79	pilot
O	80	90	randomized
O	91	101	controlled
O	102	107	trial
O	107	108	.

O	109	113	This
O	114	119	study
O	120	132	investigates
O	132	133	,
O	134	136	in
O	137	142	women
O	143	152	diagnosed
O	153	157	with
O	158	164	breast
O	165	171	cancer
O	171	172	,
O	173	176	the
O	177	188	feasibility
O	189	191	of
O	192	202	evaluating
O	203	206	the
O	207	214	effects
O	215	217	of
B-intervention	218	229	educational
I-intervention	230	238	material
O	239	242	and
O	243	246	its
O	247	255	delivery
O	256	262	method
O	262	263	,
O	264	266	on
O	267	271	bone
O	272	278	health
O	279	289	management
O	289	290	.

O	291	294	The
O	295	300	study
O	301	308	results
O	309	316	suggest
O	317	328	educational
O	329	337	material
O	338	341	may
O	342	349	improve
O	350	355	rates
O	356	358	of
O	359	363	bone
O	364	371	mineral
O	372	379	density
O	380	387	testing
O	387	388	.

O	389	400	Educational
O	401	410	materials
O	411	418	improve
O	419	423	bone
O	424	431	mineral
O	432	439	density
O	440	441	(
O	441	444	BMD
O	444	445	)
O	446	453	testing
O	454	459	rates
O	460	462	in
O	463	467	high
O	467	468	-
O	468	472	risk
O	473	481	patients
O	481	482	,
O	483	486	but
O	487	490	the
O	491	497	effect
O	498	500	is
O	501	508	unknown
O	509	511	in
O	512	517	women
O	518	527	diagnosed
O	528	532	with
O	533	539	breast
O	540	546	cancer
O	546	547	.

O	548	555	Methods
O	556	558	of
O	559	569	delivering
O	570	581	educational
O	582	591	materials
O	592	595	may
O	596	600	also
O	601	607	affect
O	608	615	testing
O	616	621	rates
O	621	622	.

O	623	626	The
O	627	635	purposes
O	636	638	of
O	639	643	this
O	644	649	study
O	650	654	were
O	655	657	to
O	658	667	determine
O	668	671	the
O	672	683	feasibility
O	684	686	of
O	687	690	the
O	691	699	protocol
O	700	703	and
O	704	706	to
O	707	712	pilot
O	712	713	-
O	713	717	test
O	718	721	the
O	722	729	effects
O	730	732	of
O	733	744	educational
O	745	753	material
O	754	757	and
O	758	761	its
O	762	770	delivery
O	771	778	methods
O	779	781	on
O	782	785	BMD
O	786	793	testing
O	794	799	rates
O	799	800	.

O	801	806	Pilot
O	807	817	randomized
O	818	828	controlled
O	829	834	trial
O	835	839	with
O	840	845	block
O	846	859	randomization
O	859	860	.

B-total-participants	861	866	Fifty
I-total-participants	866	867	-
I-total-participants	867	871	four
O	872	877	women
O	878	879	(
B-age	879	883	aged
I-age	884	886	65
I-age	886	887	-
I-age	887	889	75
O	890	893	and
B-eligibility	894	903	diagnosed
I-eligibility	904	908	with
I-eligibility	909	915	breast
I-eligibility	916	922	cancer
I-eligibility	923	924	â‰¥
I-eligibility	925	926	3
I-eligibility	927	932	years
I-eligibility	933	936	ago
I-eligibility	937	938	(
I-eligibility	938	942	2010
I-eligibility	942	943	-
I-eligibility	943	947	2012
I-eligibility	947	948	)
I-eligibility	949	952	and
I-eligibility	953	956	not
I-eligibility	957	963	taking
I-eligibility	964	976	osteoporosis
I-eligibility	977	987	medication
I-eligibility	987	988	)
O	989	993	were
O	994	1003	recruited
O	1004	1008	from
O	1009	1017	February
O	1018	1020	to
O	1021	1024	May
O	1025	1029	2016
O	1030	1033	and
O	1034	1044	randomized
O	1045	1047	to
O	1048	1053	three
O	1054	1060	groups
O	1060	1061	:
B-control	1062	1069	control
I-control	1070	1077	without
I-control	1078	1089	educational
I-control	1090	1098	material
O	1098	1099	,
O	1100	1111	educational
O	1112	1120	material
O	1121	1130	delivered
O	1131	1133	by
O	1134	1140	postal
O	1141	1145	mail
O	1145	1146	,
O	1147	1150	and
O	1151	1162	educational
O	1163	1171	material
O	1172	1181	delivered
O	1182	1184	by
O	1185	1192	patient
O	1193	1199	choice
O	1200	1202	of
O	1203	1209	postal
O	1210	1214	mail
O	1214	1215	,
O	1216	1221	email
O	1221	1222	,
O	1223	1225	or
O	1226	1230	text
O	1231	1240	messaging
O	1240	1241	.

O	1242	1249	Outcome
O	1250	1258	measures
O	1259	1263	were
O	1264	1273	primarily
O	1274	1283	evaluated
O	1284	1289	using
B-outcome-Measure	1290	1294	self
I-outcome-Measure	1294	1295	-
I-outcome-Measure	1295	1301	report
I-outcome-Measure	1302	1316	questionnaires
O	1316	1317	.

O	1318	1321	The
B-outcome	1322	1335	participation
I-outcome	1336	1340	rate
O	1340	1341	,
O	1342	1349	defined
O	1350	1352	as
O	1353	1356	the
O	1357	1367	proportion
O	1368	1370	of
O	1371	1379	eligible
O	1380	1392	participants
O	1393	1396	who
O	1397	1406	consented
O	1407	1409	to
O	1410	1421	participate
O	1421	1422	,
O	1423	1426	was
O	1427	1429	39
O	1429	1430	.
O	1430	1431	1
O	1431	1432	%
O	1432	1433	.

B-outcome	1434	1441	Primary
I-outcome	1442	1449	outcome
I-outcome	1450	1457	measure
O	1458	1461	was
O	1462	1470	obtained
O	1471	1474	for
O	1475	1477	98
O	1477	1478	%
O	1479	1481	of
O	1482	1485	the
O	1486	1495	recruited
O	1496	1501	women
O	1501	1502	.

O	1503	1509	During
O	1510	1513	the
O	1514	1515	6
O	1515	1516	-
O	1516	1521	month
O	1522	1528	follow
O	1528	1529	-
O	1529	1531	up
O	1532	1538	period
O	1538	1539	,
B-outcome	1540	1543	BMD
I-outcome	1544	1551	testing
I-outcome	1552	1557	rates
O	1558	1562	were
O	1563	1576	significantly
O	1577	1583	higher
O	1584	1586	in
O	1587	1590	the
O	1591	1597	groups
O	1598	1607	receiving
O	1608	1619	educational
O	1620	1629	materials
O	1630	1632	by
O	1633	1637	mail
O	1638	1639	(
B-iv-bin-percent	1639	1641	26
I-iv-bin-percent	1641	1642	%
O	1642	1643	,
O	1644	1646	95
O	1646	1647	%
O	1647	1649	CI
O	1650	1651	=
O	1652	1654	10
O	1655	1657	to
O	1658	1660	49
O	1660	1661	)
O	1662	1665	and
O	1666	1668	by
O	1669	1676	patient
O	1677	1683	choice
O	1684	1685	(
B-iv-bin-percent	1685	1687	18
I-iv-bin-percent	1687	1688	%
O	1688	1689	,
O	1690	1692	95
O	1692	1693	%
O	1693	1695	CI
O	1696	1697	=
O	1698	1699	5
O	1700	1702	to
O	1703	1705	41
O	1705	1706	)
O	1706	1707	,
O	1708	1712	when
O	1713	1721	compared
O	1722	1726	with
O	1727	1730	the
O	1731	1738	control
O	1739	1744	group
O	1745	1746	(
B-cv-bin-percent	1746	1747	6
I-cv-bin-percent	1747	1748	%
O	1748	1749	,
O	1750	1752	95
O	1752	1753	%
O	1753	1755	CI
O	1756	1757	=
O	1758	1759	0
O	1759	1760	.
O	1760	1761	3
O	1762	1764	to
O	1765	1767	25
O	1767	1768	)
O	1768	1769	.

O	1770	1781	Educational
O	1782	1790	material
O	1791	1794	was
O	1795	1805	associated
O	1806	1810	with
O	1811	1812	a
B-iv-bin-percent	1813	1815	17
I-iv-bin-percent	1815	1816	%
O	1817	1823	higher
B-outcome	1824	1827	BMD
I-outcome	1828	1835	testing
I-outcome	1836	1840	rate
O	1840	1841	.

O	1842	1845	The
O	1846	1851	study
O	1852	1860	protocol
O	1861	1863	is
O	1864	1872	feasible
O	1873	1876	for
O	1877	1878	a
O	1879	1884	large
O	1884	1885	-
O	1885	1890	scale
O	1891	1896	study
O	1896	1897	.

O	1898	1901	The
O	1902	1913	educational
O	1914	1922	material
O	1923	1935	intervention
O	1936	1938	is
O	1939	1946	broadly
O	1947	1955	accepted
O	1956	1958	by
O	1959	1962	the
O	1963	1968	study
O	1969	1981	participants
O	1982	1986	with
O	1987	1988	a
O	1989	1998	promising
O	1999	2007	positive
O	2008	2014	effect
O	2015	2017	on
O	2018	2021	BMD
O	2022	2029	testing
O	2030	2035	rates
O	2035	2036	.
